explore -WSS

explore

author：leisure time 2025-10-02 22:27:02 - browse：36

European Medicines Agency Suffers Cyber Attack in Amsterdam — Paulo Amorim / VWPics via AP Images

LONDON — European regulators on Friday reiterated their view that an ALS treatment from Amylyx Pharmaceuticals should not be approved, likely dooming the drug’s chances for now.

A European Medicines Agency committee had initially recommended against approving the drug, known as Albrioza, in June. Friday’s confirmation of that position came after the company appealed the decision. While the European Commission officially decides whether to approve a new medicine, it almost always follows the committee’s guidance. The final decision is expected to be made before the end of the year.

The drug, which won approval last year in the United States and is marketed Relyvrio, is designed to slow the progression of the fatal neurological condition. In its pivotal trial, patients who received the drug over 24 weeks scored about two points better on a 48-point scale of symptoms than those who got a placebo, indicating the drug slowed disease progression.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Eli Lilly to acquire Versanis in heated race for weight loss drugs

leisure time

WSS

Involuntary treatment for addiction doesn't work

Stoke drug shows lower activity against childhood epilepsy

McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources

'The boss' wants server deleted: New allegations emerge in Trump indictment

Bryan Kohberger seeks indictment dismissal in Idaho college killings case

Bryan Kohberger seeks indictment dismissal in Idaho college killings case

knowledge

explore

focus

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Can CDC director Mandy Cohen drive consensus in Washington?

Sports medicine is finally prioritizing gender equality

As the dark side of IVF slowly comes into focus, even more transparency is needed

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Ending health disparities requires full federal government, panel says

Drug repurposing or repositioning? The language matters

Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms

23andMe had bad news about my health. I wish a person had delivered it

Who gets to use the title 'doctor'?

focus

RFK Jr. accused of antisemitic claims about COVID but insists he was misunderstood

Does aspartame cause cancer? What new WHO guidance says

Public health communication lessons from Covid

Who gets to use the title 'doctor'?

Europe sees delivery challenges ahead on Alzheimer's therapies

The new HIV moral panic

focus

hotspot

leisure time

leisure time